The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
John Anthony Lust
No relevant relationships to disclose
Charles Barranco
Employment or Leadership Position - Senesco Technologies
Martha Lacy
No relevant relationships to disclose
Angela Dispenzieri
No relevant relationships to disclose
Morie A. Gertz
No relevant relationships to disclose
David Dingli
No relevant relationships to disclose
Stephen J. Russell
No relevant relationships to disclose
Francis Buadi
No relevant relationships to disclose
Steven R. Zeldenrust
No relevant relationships to disclose
Suzanne R. Hayman
No relevant relationships to disclose
S. Vincent Rajkumar
No relevant relationships to disclose
Shaji Kumar
No relevant relationships to disclose
Saad Zafar Usmani
No relevant relationships to disclose
John Thompson
Consultant or Advisory Role - Senesco Technologies (U)
Research Funding - Senesco Technologies
Catherine Taylor
Stock Ownership - Senesco Technologies
Research Funding - Senesco Technologies
Richard Dondero
Employment or Leadership Position - Senesco Technologies